A 25-year-old man was recently diagnosed with HIV and he is now presenting for an initial clinic evaluation. Baseline laboratory studies show a CD4 count of 716 cells/mm³ and an HIV RNA of 56,550 copies/mL. An HIV drug resistance genotype is pending. Approximately 3 years ago, he briefly tried tenofovir DF-emtricitabine and then tenofovir alafenamide-emtricitabine for HIV preexposure prophylaxis (PrEP) but did not tolerate either regimen well. The plan is to start antiretroviral therapy with a regimen of dolutegravir-abacavir-lamivudine.